Micro-RNA family that modulates fibrosis and uses thereof
AssigneeBoard of Regents, The University of Texas System
InventorsEric N. Olson, Eva van Rooij
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
Claims18
A method for increasing fibrotic tissue formation in the wall of a vessel in a subject having one or more soft plaques comprising delivering an antisense oligonucleotide comprising a sequence that is at least partially complementary to a miR-29a, miR-29b, and/or miR-29c sequence to one or more soft plaque sites in the vessel wall, wherein the soft plaque is converted to fibrotic tissue following delivery of the antisense oligonucleotide.
Dependencies are inferred from the claim text.